3-(1-trityl-1H-imidazol-4-yl)phenylamine | 725233-19-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 3-(1-trityl-1H-imidazol-4-yl)phenylamine
• 英文别名: 3-(1-trityl-1H-imidazol-4-yl)aniline；3-(1-tritylimidazol-4-yl)aniline
• CAS: 725233-19-2
• 化学式: C₂₈H₂₃N₃
• 分子量: 401.511
• InChiKey: MHUFOUJKWYBSTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(1-trityl-1H-imidazol-4-yl)phenylamine 在 吡啶 、 盐酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-[3-(1H-imidazol-5-yl)phenyl]ethanesulfonamide
  参考文献：
  名称：

  Synthesis and Structure−Activity Studies on N-[5-(1H-Imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidazole-Containing α_1A-Adrenoceptor Agonist

  摘要：

  Structure-activity studies were performed on the alpha(1A)-adrenoceptor (AR) selective agonist N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide (4). Compounds were evaluated for binding activity at the alpha(1A), alpha(1b), alpha(1d), alpha(2a), and alpha(2B) subtypes. Functional activity in tissues containing the alpha(1A) (rabbit urethra), alpha(1B) (rat spleen), alpha(1D) (rat aorta), and alpha(2A) (rat prostatic vas deferens) was also evaluated. A dog in vivo model simultaneously measuring intraurethral pressure (IUP) and mean arterial pressure (ALAP) was used to assess the uroselectivity of the compounds. Many of the compounds that were highly selective in vitro for the alpha(1A)-AR subtype were also more uroselective in vivo for increasing IUP over MAP than the nonselective alpha(1)-agonists phenylpropanolamine (PPA) (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater alpha(1A) selectivity would reduce cardiovascular side effects. However, the data also support a prominent role of the alpha(1A)-AR subtype in the control of MAP.

  DOI：

  10.1021/jm030551a
• 作为产物：
  描述：

  3-氨基苯硼酸 、 4-溴-1-三苯甲基-1H-咪唑 在 tris-(dibenzylideneacetone)dipalladium(0) 、 tri tert-butylphosphoniumtetrafluoroborate potassium fluoride 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以36%的产率得到3-(1-trityl-1H-imidazol-4-yl)phenylamine
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE
  [FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT UN COEUR PYRROLOPYRIDINE OU BENZIMIDAZOLE

  摘要：

  本发明涉及式(I)化合物及其药用盐，其中R1、R2、R3、R4、R5和n的定义如本文中所述。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的方法以及在这些过程中有用的中间体。

  公开号：

  WO2011071725A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT UN COEUR INDOLE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011071716A1

  公开（公告）日：2011-06-16

  Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

  公开了抑制RSK的新颖化合物，制造此类化合物的方法以及包含此类化合物的药物组合物。还公开了使用本发明的化合物治疗RSK2调控失调的方法。
• HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE
  申请人：Boyer Stephen James

  公开号：US20130137680A1

  公开（公告）日：2013-05-30

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及公式（I）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5和n的定义如本文所述。本发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及用于这些过程的中间体。
• Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
  申请人：Boyer Stephen James

  公开号：US09073926B2

  公开（公告）日：2015-07-07

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5和n的定义如本文所述。本发明还涉及包含这些化合物的制药组合物、使用这些化合物治疗各种疾病和障碍的方法、制备这些化合物的过程以及在这些过程中有用的中间体。
• HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE
  申请人：Boyer Stephen James

  公开号：US20130109679A1

  公开（公告）日：2013-05-02

  Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

  本发明揭示了一种新型化合物，可抑制RSK，制备这种化合物的方法以及包含这种化合物的药物组合物。本发明还揭示了使用本发明化合物治疗RSK2调节的疾病的方法。
• Heterocyclic compounds containing an indole core
  申请人：Boyer Stephen J.

  公开号：US09150577B2

  公开（公告）日：2015-10-06

  Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.

  本发明涉及一种新型化合物，其可以抑制RSK，并且涉及制备这种化合物的方法以及包含这种化合物的制药组合物。本发明还涉及使用本发明的化合物治疗RSK2调节的疾病的方法。